Latest news with #medicalTechnology
Fox News
07-07-2025
- Health
- Fox News
How micro-robots may soon treat your sinus infections
A breakthrough in medical technology could soon change how sinus infections are treated. Scientists have created micro-robots for sinus infection treatment that can enter the nasal cavity, eliminate bacteria directly at the source, and exit without harming surrounding tissue. This drug-free, targeted approach may reduce our dependence on antibiotics. Sign up for my FREE CyberGuy ReportGet my best tech tips, urgent security alerts, and exclusive deals delivered straight to your inbox. Plus, you'll get instant access to my Ultimate Scam Survival Guide - free when you join my These microscopic robots are smaller than a speck of dust. They are made of magnetic particles enhanced with copper atoms. Doctors insert them through a narrow duct in the nostril. Once inside, the micro-robots are guided by magnetic fields to reach the infected area. At that point, a fiber optic light heats the particles and triggers a chemical reaction. This reaction breaks through thick mucus and destroys harmful bacteria at the infection site. As a result, treatment becomes faster, more precise, and far less invasive. This latest advancement comes from a collaboration of researchers at the Chinese University of Hong Kong, along with universities in Guangxi, Shenzhen, Jiangsu, Yangzhou, and Macau. Their work, published in "Science Robotics," has helped move micro-robotic medical technology closer to real-world applications. Traditional antibiotics circulate throughout the entire body. In contrast, micro-robots target only the infected area. This reduces side effects and lowers the risk of antibiotic resistance. Furthermore, patients may recover faster because the treatment goes straight to the source. So far, animal trials have shown promising results. Micro-robots successfully cleared infections in pig sinuses and live rabbits, without causing tissue damage. However, scientists still need to ensure that every robot exits the body after treatment. Leftover particles could pose long-term risks. In addition, public acceptance remains a challenge. The idea of tiny machines inside the body makes some people uncomfortable. Nevertheless, experts believe those fears will fade over time. Researchers are already exploring how micro-robots could treat infections in the bladder, stomach, intestines, and bloodstream. Several teams around the world are working to make the technology more advanced and adaptable for deep internal use. If successful, these innovations could revolutionize the way we fight bacteria in the human body. The rise of micro-robots for sinus infection treatment marks a major shift in medical care. By offering precise, non-invasive therapy without antibiotics, this method could redefine how infections are treated. With continued research and testing, these tiny tools may soon become powerful allies in modern medicine. Would you let microscopic robots crawl through your sinuses if it meant never needing antibiotics again? Let us know by writing to us at Sign up for my FREE CyberGuy ReportGet my best tech tips, urgent security alerts, and exclusive deals delivered straight to your inbox. Plus, you'll get instant access to my Ultimate Scam Survival Guide - free when you join my Copyright 2025 All rights reserved.
Reuters
01-07-2025
- Business
- Reuters
Brainlab CEO in internal memo blames geopolitical uncertainties for putting IPO on ice
MUNICH, Germany, July 1 (Reuters) - The CEO of German medical technology firm Brainlab said on Tuesday that geopolitical uncertainties had prompted the decision to put on hold its planned initial public offering, adding that business in the last quarter looked positive. "We have to recognise that the current geopolitical uncertainties continue to have a significant impact on the international capital markets," wrote Rainer Birkenbach in an internal memo seen by Reuters, adding that at this time, an IPO did not offer optimal conditions for the company.
Yahoo
25-06-2025
- Business
- Yahoo
Stryker receives FDA clearance for Incompass Total Ankle System
Streamlining total ankle replacement with data-driven implants and surgical flexibility PORTAGE, Mich., June 25, 2025--(BUSINESS WIRE)--Stryker (NYSE:SYK), a global leader in medical technologies, announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Incompass® Total Ankle System, an implant intended for patients with ankle joints damaged by severe rheumatoid, post-traumatic, or degenerative arthritis. This new platform integrates the innovative technologies of Stryker's Inbone® and Infinity® systems into a single, comprehensive solution for total ankle replacement. "Incompass reflects our commitment to redefining what's possible in total ankle replacement," said Adam Jacobs, vice president and general manager of Stryker's Foot & Ankle business. "By building on decades of clinical experience and leveraging extensive data insights, we're setting a new standard—one that empowers surgeons to deliver more personalized care with greater efficiency and confidence." Incompass incorporates Adaptis® Boney Ingrowth Technology and redesigned instrumentation to support long-term fixation, surgical flexibility and streamlined workflow. Developed to address key challenges in total ankle replacement, including intraoperative adaptability and procedural efficiency, the system is informed by data from more than 85,000 CT scans¹ and 100,000 clinical cases.¹ It also offers a broad range of implant and instrumentation options to support patient-specific care. Built using the Stryker Orthopaedic Modeling & Analytics (SOMA) platform in combination with arthritic ankle scans from the company's Prophecy Surgical Planning System, Incompass provides a continuum of implant and instrument options designed to accommodate both surgeon preference and patient anatomy. System enhancements include a redesigned alignment system for greater control across multiple planes, updated implant holders and trial tools for improved handling, and instrumentation refinements designed to reduce surgical steps and set up time. About Stryker Stryker is a global leader in medical technologies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in MedSurg, Neurotechnology, and Orthopaedics that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 150 million patients annually. More information is available at Copyright © 2025 StrykerContent ID: FA-INCO-PRESS-2016296 References:1. Based on internal data as of 5/1/2025. View source version on Contacts Media contact Sampson Public Relations GroupAndrea SampsonPresident/CEO asampson@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
18-06-2025
- Business
- Associated Press
ANACONDA Biomed Receives CE Mark for Its ANA5 Funnel Catheter to Treat Ischemic Stroke
BARCELONA, Spain--(BUSINESS WIRE)--Jun 18, 2025-- ANACONDA Biomed, a medical technology company developing next-generation thrombectomy systems for the treatment of ischemic stroke, has announced that it has received CE Mark certification for its ANA5 Funnel Catheter. The CE marking confirms that the ANA5 device complies with the European Union's health, safety, and environmental protection standards, enabling its eventual commercial viability across the EU. This press release features multimedia. View the full release here: The ANA5 Funnel Catheter is engineered to optimize mechanical thrombectomy by maximizing clot capture with its vessel-matching diameter funnel. Simultaneously, it enables antegrade flow arrest and offers the potential for flow reversal, enhancing aspiration-assisted clot retrieval. The ANA5 promotes improved clot capture and removal through its unique proprietary geometry. The ANA5 Funnel Catheter is engineered to optimize mechanical thrombectomy by maximizing clot capture with its vessel-matching diameter funnel. Simultaneously, it enables antegrade flow arrest and offers the potential for flow reversal, enhancing aspiration-assisted clot retrieval. The ANA5 promotes improved clot capture and removal through its unique proprietary geometry. The CE Mark approval is supported by a comprehensive body of evidence, including preclinical bench and animal studies, and clinical data from the recently published ANAIS study demonstrating high reperfusion and first-pass success rates. Further clinical validation is ongoing in the ATHENA trial, a prospective, multicenter randomized study systematically evaluating the impact of proximal flow arrest on reperfusion effectiveness, to support future regulatory submissions and commercialization efforts in the United States. ' Receiving CE Mark approval is a pivotal achievement for ANACONDA Biomed thatadvances our mission to innovate in the interventional management of acute ischemic stroke,' said Trent Reutiman, chief executive officer. " This milestone reflects the strength of our science and the dedication of our team. We now have the capability of making ANA5 available to clinicians across Europe, bringing this innovative technology to broader stroke application.' Dr. Marc Ribo, the co-founder of Anaconda Biomed, added, " Receiving CE Mark approval for ANA5 is deeply meaningful, as it represents the culmination of years of research, iteration, and belief in an idea that began at the bench. This is more than a regulatory milestone; it's the moment where innovation becomes impact. We're now gearing up to capture real-world data by collecting more invaluable insight into how ANA5 performs across diverse stroke centers and clinical realities. ' About ANA Funnel Catheter ANA5 Advanced Neurovascular Access™ (ANA Funnel Catheter) is designed as an expandable and collapsable funnel catheter for interventional neurovascular procedures, requiring the retrieval of clot, and benefiting from limiting flow and/or flow reversal towards that goal. The device consists of a radiopaque nitinol braid funnel, covered with a polymeric coating enabling local flow arrest. The catheter is currently an investigational device and is not available for sale in the United States. About Anaconda Biomed Anaconda Biomed is an innovative medical technology company dedicated to developing next-generation thrombectomy systems for the treatment of ischemic stroke. At the heart of its product portfolio is the ANA Funnel Catheter. Anaconda Biomed has received funding from prominent life science investment firms, including Ysios Capital, Omega Funds, Innogest, Asabys Partners, Banco Sabadell, and private investors. Additionally, through public grants, the company has received significant public support from ENISA, CDTI (Innvierte and NEOTEC), the Ministry of Science & Innovation (Emplea and Retos), EIB, and EIT Health. For more information, please visit and follow the company on LinkedIn. View source version on CONTACT: MEDIA CONTACT: Joe Duraes Pazanga Health Communications [email protected] 917-687-6419 KEYWORD: SPAIN EUROPE INDUSTRY KEYWORD: SURGERY MEDICAL DEVICES HEALTH CLINICAL TRIALS CARDIOLOGY SOURCE: Anaconda Biomed Copyright Business Wire 2025. PUB: 06/18/2025 07:05 AM/DISC: 06/18/2025 07:03 AM
News.com.au
07-05-2025
- Business
- News.com.au
Dr Boreham's Crucible: The strategy is clear for this x-ray imaging house – can it see it through to profitability?
Many life science companies stress the virtue of diversity: multiple programs to protect against one of them failing. Diversity can be helpful: after its failed phase III eye disease programs, Opthea would be wishing it had another drug candidate up its sleeve. But chasing too much stuff can spread resources too thinly and create investor confusion. Just last month Clarity Pharmaceuticals ditched neuroblastoma and some prostate cancer programs from its crowded radiotherapy rota and Clinuvel Pharmaceuticals paused its stroke program. In the case of Micro-X (ASX:MX1), as part of a 'strategy re-set' the x-ray imaging house has focused on medical applications, rather than security and defence uses such as bomb and baggage screening. 'The tech we have developed has fantastic applications in medical, security and defence,' CEO Kingsley Hall says. 'We have decided that while our technology enables applications in all those fields, we can impact medical the quickest and the best. 'While the security industry is quite large, it tends to be slowest to move and has some significant incumbents.' About Micro-X Micro-X has commercialised two mobile digital radiology (DR) devices: the first-generation Nano and a sturdier iteration called Rover. Based in the Adelaide suburb of Tonsley, Micro-X listed on December 21, 2015, having raised $20 million at 50 cents apiece. Along the way, Micro-X entered several alliances and distributorships, including with Carestream Health Inc (formerly Kodak Medical Imaging), MXR Imaging Inc and listed French x-ray equipment manufacturer DMS Imaging SA. Inaugural CEO Peter Rowland oversaw development of four separate uses for the company's revolutionary cold-cathode x-ray technology. Amid investor frustration about slow progress, in May 2023 Mr Rowland stepped down in favor of chief financial officer Kingsley Hall. In September 2022, Micro-X inked a deal with Nasdaq listed x-ray component supplier Varex Imaging Corp, by which Varex took a 9.9% equity stake for a $15 million outlay. Hot to trot on cold cathodes In a century-old process, x-rays are generated with a heated filament cathode that generates electrons in a vacuum tube. The process is inefficient because of wasted heat and the electrons don't all move in the right direction. Micro-X's cold cathode technique is based on four-nanometre wide carbon tubes, under an electrified fine mesh structure. While standard computed tomography (CT), scanners use only one x-ray source to rotate around an object. Micro-X's tubes enable x-ray beams to be fired from different angles with no moving parts. The tubes are substantially smaller and lighter and are controlled electronically - rather than via heat - and can be turned on and off instantly. Rover runs well in the field A lightweight 'ruggedised' version of the Nano, Rover is proving its mettle in the Ukraine conflict. Initially funded by two US-based charities, Micro-X delivered 13 Rovers to the Ukraine in late 2022, followed by 16 more Australian government-funded units last year. 'The feedback from surgeons using them on the frontline has been phenomenally positive,' Hall says. 'One of them was used 6000 times in its first month.' In toto, Micro-X has sold 400 Rovers in 39 countries, with the US comprising the biggest market. The company also has European Union approval for Rover, but it's a 'large and difficult market.' The company is awaiting formal feedback to undergo a large formal trial in the US, with an unnamed hospital group. … and he's a good sport Another Rover application is on the sporting field rather than battlefield, with about one third of US Major Baseball League teams deploying the units to examine player injuries. Rover was also the mobile digital radiology units of choice for the recent National Collegiate Athletics Association's US basketball championships. Rover has also been used in driver's pits at grand prix events. 'It's found a really nice niche among professional sporting teams and associations,' Hall says. Baseball and basketball may not be contact sports, but hand and feet injuries abound. Rover means teams may not have to send players to hospital for an x-ray and may be able to get them back on the field. 'World first' full body CT: image-in that? In early December last year, the US Advanced Research Projects Agency for Health (ARPA-H) awarded the company up to US$25 million over five years to develop the world's first portable full-body computed tomography (CT) scanner. The first US$8 million is in the bank and the rest depends on meeting 'technical objectives' and US Food and Drug Administration approval. The compact is part of the US government's 'Paradigm' program, to take hospital-grade computed tomography into regional America. Hall says that to be selected, the unit needed to be at least 80% lighter than a traditional computed tomography device, which typically weighs a tonne. And for anyone wondering about the security of the funding, it helps that regional America is Donald Trump's voting heartland. Stroke me Micro-X is building three prototype versions of its portable stroke units, which will be used in three planned local hospital trials. Current stroke detection CT scanners weigh 600 kilograms and need a crew of five. Oh – and they cost $1.5 million. Micro-X's so-called ring scanner weights 75kg, is much cheaper and emits 85% less radiation. In December, the first stroke patient was successfully imaged. The trials will entail suspected stroke victims being subject to standard CT imaging, then overlaid with the Micro-X scan. Aiming for 'several hundred' scans, the studies only need to prove that the Micro-X tech is just as good as the conventional ones. In essence, the scans aim to distinguish clot strokes, the most common, from bleeds. This is crucial because a clot can be treated with blood thinning drugs, but for a bleed patient, that could be fatal. The program is backed by the Australian Stroke Alliance (ASA) and the Australian Medical Research Future Fund (MRFF). Shedding the baggage Initially funded by the US Department of Homeland Security to the tune of US$29 million, Micro-X's self-service baggage scanning program has been far from wasted. In February, the company struck a deal with Malaysian logistics company Billion Prima Sdn Bhd to develop the technology. The compact involves Billion Prima taking a $2.4 million equity stake in Micro-X – just under 4% of the company - at nine cents a share (a 15% premium). Prima will pay Micro-X up to $3.2 million to develop a baggage scanner for them, over the next 12 months. If successful, the units would be distributed to up-to nine South East Asian countries. 'I think they will be very good partners,' Hall says. 'But we have also had other good ongoing conversations bout monetising other parts of our security assets … in the short to medium term.' Bombs away Micro-X won't spend any more money on its Argus bomb detection program, but that doesn't mean it's been detonated altogether. A lightweight self-contained camera carried by a robot, Argus can detect a suspicious object in 10 seconds – and up to 1500 metres away. The Australian Defence Force provided initial seed funding for Argus, which was launched in early 2024. But the company quickly realised there wasn't enough demand. 'The product was well engineered and well-resourced, and it did what it set out to do,' Hall said. 'While the product was being developed, the environment changed'. The 'problem' is that terrorist activity has lessened, meaning bomb threats aren't as prevalent. Yay everyone! 'We still think the technology is of great value and well will seek to commercialise it, outside of Argus as a product,' Hall says. 'But we are not actively marketing it.' Finances and performance Micro-X recorded revenue for the six months to December 31, 2024 of $3.96 million, 51.7% lower year-on-year. Partly explaining the decline, the previous period included a $2.8 million government Rover contract. The company lost $8.68 million, compared with a $7.66 million deficit previously. The revenue included $995,000 from Rover sales and $2.96 million of 'engineering service income': $300,000 from the ASA and $2.666 million from the US DHS. In March, the company completed a placement and rights offer that raised $6.4 million at seven cents a share, a 10% discount. This was over and above the $2.4 million placement to Prima. The retail rights stanza raised only $620,000 of the maximum $2.74 million. In December, the company pocketed a $6.4 million federal R&D tax rebate. The accounts record a $1.5 million loan, which is an advance on this year's expected refund. In February, the company also received $1 million from Prima as the first instalment in the development deal. Over the last 12 months Micro-X shares have traded between a low of 5.0 cents (mid-September last year) and 9.7 cents in early December. The latter reflects a 70% share surge after the ARPH funding announcement. Not tariff-ic, but we can live with it Micro-X makes its goods – tubes, generators and high voltage – in Adelaide, with more than 90% of its input materials sourced from Australia. Hall says of the presumed 10% tariff: 'It's difficult. But it's not as bad as our European and Asian trading partners. 'Our cost position relative our competitors is good, so … it is not a game stopper.' What's your favourite? Rather than nominating his favourite program, Hall says the real hero is the company's underlying technology. Over time, the company has evolved from making and refining the tubes, to making the high voltage generators and switching between the tubes 'We have three tubes but are developing a fourth one,' he says. 'They are different in size and shape and what they do … but the underlying tech and applications are the same.' While the head (stroke) CT has 21 tubes, the full-body scanner has more than 100. 'Also, the majority of our software is constructed in-house,' Hall says. 'We are really focused on the technology platform and how that transforms into medical products.' Dr Boreham's diagnosis Hall says the company is looking for 'positive and profitable' applications for its technology. Who could argue with that? 'Our goal is to make great imaging products that are better than our competitor,' he says. 'We think all three of our current medical products will be strong for us and the demand will grow as each one enhances our position in the market.' Micro-X has done well to attract non-dilutive funding from various sources. But as is almost the case in the medical device game, progress to profitability has been slower than expected, 'There's a lot going on, but we have to get on with it and demonstrate some real positive results,' Hall says. At a glance ASX code: MX1 Share price: 6.0 cents Shares on issue: 664,173,290 Market cap: $39.85 million Chief executive officer: Kingsley Hall Board*: Patrick O'Brien (chair), Jim McDowell, Illona Meyer, Andrew Hartmann * Dr Alexander Gosling and David Knox left in November 2024 and January 2025, respectively Financials (December 2024 half year): Revenue $3.96 million (down 51.7%), net loss $8.68 million ($7.66 million deficit previously), 1.59 quarters cash at March 31, 2025 Identifiable major holders: Perennial Value Management 12.9%, Acorn Capital 10.85%, Varex Imaging 9.3%, Tiga Trading/Thorney 7.76%, Peter Rowland 2.4%
